月別アーカイブ: 2014年2月

3 Pharma ETFs Beating the Market

After the incredible surge in 2013, the healthcare sector is no doubt crushing the overall market this year too. This is largely thanks to the bullish trend in both the pharma and biotech segments and robust performances by major drug companies (read: 3 Top Ranked Healthcare ETFs in Focus).
 
Total fourth quarter earnings for the medical sector reported so far are up 1% with a beat ratio of 74.5% while revenues are up 6% with a beat ratio of 72.3%. Though biotech stocks continued their strong performances, pharma stocks have shown a strong turnaround from the recent patent cliffs and became the darlings of the financial market of late.
 
Encouraging Trends
 
Increasing merger and acquisition activities, promising new drugs and their approval, restructuring, increased pipeline visibility, aging population and expansion into emerging markets are boosting confidence in the pharma sector.  
 
In addition, the Affordable Care Act (often known as Obamacare) – which ensures a larger base of insured persons across the U.S. – is fueling growth. With expanded healthcare coverage, this corner of the healthcare space will likely be a huge beneficiary, boosting sales for many drug companies, as drugs would be accessible to a large number of Americans (read: Obamacare Will Be Amazing for These Stocks and ETFs).
 
Further, the bullish trend for the sector is confirmed by the Zacks Industry Rank, as pharma has one of the best ranks for any industry at the time of writing. Three out of four Zacks industries that are classified under pharma have Zacks Ranks in the top 37%, suggesting solid trading for this segment in the coming months.
 
Moreover, the sector might be a good defensive play in order to withstand the current volatility in the market arising from the Fed’s unwinding monetary stimulus and the recent sluggish U.S. economic data.
 
Top Pharma ETFs to Consider
 
Given this favorable position of the pharma industry, investors may want to consider some of the ETFs tracking this space for exposure. While there a number of quality choices in the space, we have highlighted some of our favorite top performing pharma ETFs below, any of which could make for excellent investments in today’s growth-focused market (see: all the Healthcare ETFs here):
 
SPDR S&P Pharmaceuticals ETF (XPH)
 
The fund tracks the S&P Pharmaceuticals Select Industry Index, holding 33 securities in its basket. The product has $913.3 million in AUM and trades more than 110,000 shares in volume a day, while its cost is just 35 basis points a year.
 
The product is pretty well spread across each security as the top 10 holdings account for nearly 43% of the total assets. Forest Laboratories (FRX), Jazz Pharmaceuticals (JAZZ) and Questcor Pharmaceuticals (QCOR) occupy the top three positions in the basket with a combined 14.58% share. While large caps account for 44% of total assets, small and mid caps take the remainder.
 
The product gained about 13% so far in the year and has a Zacks ETF Rank of 2 or ‘Buy’ rating with ‘Low’ risk outlook.
 
iShares U.S. Pharmaceuticals ETF (IHE)
 
This ETF tracks the Dow Jones U.S. Select Pharmaceuticals Index and holds 36 securities in its basket. The product has amassed $659 million in its asset base while volume is relatively light at less than 24,000 shares a day on average. The fund charges 45 bps in fees per year from its investors (read: A Comprehensive Guide to Pharma ETFs). 
 
In terms of individual holdings, the top three holdings – Johnson & Johnson (JNJ), Pfizer (PFE) and Merck (MRK) – together make up for 29.64% share in the basket, suggesting heavy concentration. IHE is a large cap-centric fund accounting for 68% of the assets. Though pharmaceuticals make up for a substantial 93% share, biotech receives a minor allocation.
 
The ETF gained nearly 11.30% year-to-date and has a decent Zacks ETF Rank of 3 or ‘Hold’ rating with ‘Low’ risk outlook.
 
PowerShares Dynamic Pharmaceuticals Fund (PJP)
 
This is by far the most popular choice in the pharma corner of the healthcare segment that follows the Dynamic Pharmaceuticals Intellidex Index. The product has a good level of AUM of about $1.2 billion and sees solid volume of roughly 216,000 shares a day. The fund charges 63 bps in fees and expenses from investors.
 
With holdings of 29 stocks, the fund is moderately concentrated in the top 10 holdings and focuses more on large caps with 62% of total assets. Biogen (BIIB), Merck and Gilead Sciences (GILD) are the top three components in the basket, accounting for nearly 5% share each. In terms of industrial exposure, 68% of assets are allocated to pharmaceuticals while 27% and 5% are allotted to biotechnology and medical equipment, respectively.
 
The product added nearly 11% so far this year. PJP has a Zacks ETF Rank of 3 or ‘Hold’ rating with ‘Low’ risk outlook.
 
 
 
Bottom Line
 
These products are clearly outpacing the broad market fund (SPY) and the broad sector fund (XLV) by wide margins (read: 3 Sector ETFs Surging to Start 2014). This trend is likely to continue in the coming months given the recent market volatility and the promises made by Obamacare, solid industry rank, and M&A opportunities in this corner of the investing world.
 
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Read the analyst report on XPH

Read the analyst report on PJP

Read the analyst report on IHE

Zacks Investment Research

 
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Source Article from http://finance.yahoo.com/news/3-pharma-etfs-beating-market-224839921.html
3 Pharma ETFs Beating the Market
http://finance.yahoo.com/news/3-pharma-etfs-beating-market-224839921.html
http://news.search.yahoo.com/news/rss?p=pharma
pharma – Yahoo News Search Results
pharma – Yahoo News Search Results



Research and Markets: The US Pharmacy Benefit Management (PBM) Industry Report: 2013 Edition

DUBLIN–(BUSINESS WIRE)–

Research and Markets (http://www.researchandmarkets.com/research/qvqtbd/the_us_pharmacy) has announced the addition of the “The US Pharmacy Benefit Management (PBM) Industry Report: 2013 Edition” report to their offering.

In the US, a third party administrator of prescription drug program is known as a Pharmacy Benefit Manager (PBM). The primary responsibilities of a PBM include processing and paying prescriptions drug claim, developing and maintaining formulary, negotiating discounts and rebates with drug manufacturers and pharmacies. The US prescription volume has witnessed an unprecedented growth over the past few years and the same pattern is likely to continue in the near future. Therefore, through rebates from pharmaceutical manufacturers, price discounts from retails, and effective mail service pharmacies, the PBMs ceaselessly focus on enabling the plan sponsors and individuals to obtain prescribed drugs at lower prices.

In order to improve the value of drug benefit and manage the cost and utilization of prescribed drugs, PBMs offer a wide range of tools and techniques. These techniques include pharmacy network, plan design, electronic prescribing, manufacturer discounts, and clinical management. The US PBM industry is highly fragmented with about 100 major companies operating in the marketplace, out of which some are independently owned and operated while others are subsidiaries of major chain drug store, retail outlets and, managed care plans.

The key factors driving growth of PBM industry include accelerating US aging population, prevalence of chronic disease, increased life expectancy, healthcare reforms and increasing healthcare expenditure. Some of the noteworthy trends and developments of this industry include rising Medicare enrollment, generic drug utilization, increased acceptance of specialty drugs and ongoing merger & acquisition activities.

Key Topics Covered

1. Overview

1.1 History of PBM

1.2 PBM Managers

1.3 Retail Dispensing Process & Flow of Funds

1.4 Mail Dispensing Process and Flow of Funds

2. The US PBM Market Size

2.1 PBM Market by Value

2.2 PBM Market by Volume

2.3 Generic Drugs

2.4 Specialty Drugs

3. Market Dynamics

3.1 Growth Drivers

3.2 Trends and Developments

4. Competitive Landscape

4.1 Competition by Prescription Volume

4.2 Competition by Claims

4.3 Competition by Lives Managed

4.4 Competition by Specialty Pharmacy Drug Spending

4.5 Competition by Health Plans

4.6 Analysis of PBMs Operating Statistics

4.7 Competition by Customer Segment Mix

5. Company Profiles

Companies Mentioned

– Catamaran

– CVS Caremark

– Express Script

For more information visit http://www.researchandmarkets.com/research/qvqtbd/the_us_pharmacy

About Research and Markets

Research and Markets is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Source Article from http://finance.yahoo.com/news/research-markets-us-pharmacy-benefit-105000633.html
Research and Markets: The US Pharmacy Benefit Management (PBM) Industry Report: 2013 Edition
http://finance.yahoo.com/news/research-markets-us-pharmacy-benefit-105000633.html
http://news.search.yahoo.com/news/rss?p=pharmacy
pharmacy – Yahoo News Search Results
pharmacy – Yahoo News Search Results





Global Pharma Congress is Coming in May in Shanghai

SHANGHAI , Feb. 26, 2014 /CNW/ – Organized by UBM China and CPhI Conferences, Global Pharma Congress 2014 will be held on 28-29th May in Shanghai . This summit will integrate CPhI Global Resources and display 3 influential conferences under one roof. It will be a fabulous event not to be missed in 2014.

(Logo: http://photos.prnasia.com/prnh/20140226/0861401042LOGO )

Quality by Design (QbD) has been the consensus of pharmaceutical industry. Due to increase of APIs and formulation export, it is necessary for pharmacy to master the methodology of QbD. Also, challenges from new GSP by CFDA and EU GDP influence the whole pharmacy supply/cold chain and drug distribution. At present, coverage of pharma cold-chain has reached 10% in China and nearly 20% drug quality problems are related to it, cold chain technology improvement is very urgent. Moreover, how to realize product differentiation and enhance research & commercialization level by making use of the latest DDS and formulation strategy has become an urgent problem for pharmacy. Application of new technology like sustained/controlled release, nanoparticles and new material implantation also inspire on industry.

Due to the success of 2 years Pharma QbD, 4 years Pharma Supply Chain & 4 years Pharma Cold Chain and 4 years NDDS, CPhI Conference will do the portfolio management of these pharmaceutical events to provide Global Pharma Congress on May 28-29, 2014 . The three hot topics will be included in it and this event will make connection of different departments/functions of drug manufacturer. It is a good opportunity to accelerate communication of pharmaceutical industry and promote industry interaction

Agenda At-A-Glance

Global Pharma Congress, portfolio Management of CPhI global resources, to provide you a congress covering pharma R&D, manufacture and distribution!

Contact Information:

Sally Chen
Phone Number: +86-21-61573930
Email: askconference@ubm.com

SOURCE UBM China

Contact:

http://photos.prnasia.com/prnh/20140226/0861401042LOGO

Source Article from http://finance.yahoo.com/news/global-pharma-congress-coming-may-070000270.html
Global Pharma Congress is Coming in May in Shanghai
http://finance.yahoo.com/news/global-pharma-congress-coming-may-070000270.html
http://news.search.yahoo.com/news/rss?p=pharma
pharma – Yahoo News Search Results
pharma – Yahoo News Search Results